Burnout has already contributed to a reduction in the workforce dedicated to caring for patients living with diabetes. Marie Brown, MD, of the American Medical Association will explain how to effectively address clinical burnout at an organizational level using real-world examples of success centered on practice efficiency.

A panel of nephrology and diabetes experts, including Titilayo O. Ilori, MD, MSc, will discuss the impact of race, ethnicity, and underrepresentation of vulnerable populations in clinical trials in relation to diabetes and kidney disease.

During a special Saturday morning lecture, American Diabetes Association® President of Health Care & Education Janet Brown-Friday, RN, MSN, MPH, urged the medical community to be inclusive of sex and gender, race and ethnicity among staff and participants when recruiting for trials. This also includes helping make access to trials more available to participants.

A. Enrique Caballero, MD, advocates for thoughtfully designed diabetes education and prevention programs tailored to “speak to” the different audiences for which they are intended in order to optimize diabetes care and achieve better outcomes. He is the recipient of this year’s Outstanding Educator in Diabetes Award.

Various self-assessment tools exist to help patients with diabetes monitor their daily activities and provide their care teams with insights into glucose levels. Methods for tracking behavioral markers include sleep monitoring and actigraphy devices to track physical activity. Soohyun Nam, PhD, APRN, ANP-BC, FAHA, FAAN, discussed ecological momentary assessments.

Dietary choices are crucial for managing type 2 diabetes. Experts including Roy Taylor, MD, shared their perspectives on nutrition programs that have helped patients reduce or manage type 2 diabetes while also living healthier lives. These programs incorporate low-calorie diets, low-carb diets, and glycemic excursion minimization.

Vanita R. Aroda, MD, will share results from two trials, OASIS 1 and PIONEER PLUS, and discuss the effectiveness of higher dose semaglutide in treating patients with type 2 diabetes as well as patients with obesity without type 2 diabetes. She will discuss how a high-dose semaglutide regimen can help patients reach their health goals.

Forty years after the launch of the Diabetes Control and Complications Trial, the Epidemiology of Diabetes Interventions and Complications study continues to observe and report on 1,000 patients. Gayle Lorenzi, RN, CDCES, who manages the San Diego DCCT/EDIC site, and other investigators will discuss how the data gleaned from this sustained research has transformed management…

Raphael Scharfmann, PhD, will provide insight on the earliest beta cells: fetal pancreatic beta cells. His focus will be on the human fetal pancreas and what it can reveal about beta-cell identity. Other panelists will discuss postnatal beta cells and beta-cell aging.

A panel of experts will take a closer look at changes to the American Diabetes Association® Standards of Care in Diabetes. Eric L. Johnson, MD, said that while many cornerstones of diabetes care remain in place, several topics warrant new emphasis, including sleep health, social determinants of health, hypertension, and medications.